The present findings indicate that some primary bone tumors may offer new therapeutic targets for denosumab, and suggest that denosumab may be effective for tumors expressing RANKL and involving bone resorption by osteoclasts. This evidence concerns the gene TNFSF11 and bone neoplasm.